GMMMG logo

NHS photos

NHS logo

News

<< Back

News Summary

From this page you will be able to access a summary of additions or changes to the GMMMG website during February 2017

February 2017

 

Formulary and Managed Entry Subgroup

22.2.17

Formulary

The following formulary amendments have been approved:

  • The GMMMG formulary has been updated to reflect NICE TA417, NICE TA418 and NICE TA 419.
  • The MHRA update from December has been linked within the formulary within the relevant chapters.
  • Aripiprazole 5,10 and 15mg tablets have been moved to joint first line instead of as alternative. NB Aripiprazole 30mg tablets, orodispersible and liquid preparations remain as alternative preparations.
  • Treclin® Gel has been included in the GMMMG formulary for use in moderate to severe acne and for whom other combination products (topical antibacterial and benzoyl peroxide) have failed or are not tolerated and where a topical antibacterial/retinoid combination is indicated.

RAG list

Following a period of consultation the following RAG status decisions were approved at the first meeting of the FMESG.

  • Linezolid was given a RED RAG status.
  • Octreotide for acromegaly  was given a RED RAG status (NHS E commissioned)
  • Oral Ketoconazole for Cushing’s disease was given a RED RAG status decision
  • Degaralix was given an AMBER RAG status decision – please see NICE TA criteria for use
  • Metoject for psoriasis and psoriatic arthritis  was given an AMBER RAG status decision 
  • Nivolumab was given a RED RAG status decision.
  • Brivaracetam – see NTS recommendation this was given a GREEN (following specialist initiation) RAG status decision
  • Ulipristal for intermittent treatment of moderate to severe uterine fibroids – see NTS recommendation and protocol for use; this was given a GREEN (following specialist initiation) RAG status for appropriate patients. NB the indication for pre-surgery use remains RED.

The subgroup is still looking for more GP’s as the ones that had put themselves forward are now unable to make the dates. If you are interested in being involved in this dynamic GMMMG Subgroup please contact the professional secretary on rdtc.rxsupp@nuth.nhs.uk


Pathways and Guidelines Development Subgroup

21.2.17

The following revised and updated Shared Care Protocols were approved at the February 2017 meeting of the GMMMG:

16.2.17

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Guideline for Degarelix in advanced hormone dependent prostate cancer is in development. We now seek the comments of all GM NHS healthcare professionals on this. This consultation period is open until 5:00pm on Friday 31st March 2017. Comments should be submitted here after which it will be reviewed, amended as required and then taken to GMMMG for final approval. The Pharmaceutical Industry is invited to comment on factual inaccuracies only.

16.2.17

On behalf of the GMMMG Pathways and Guidelines Development Subgroup, a Greater Manchester wide Shared Care Guideline for  Nebulised Colistin – Colistimethate sodium (Colomycin® or Promixin®) for the treatment of Pseudomonas Aeruginosa colonisation and infection in adult patients with non-CF bronchiectasis or bronchial sepsis is in development. We now seek the comments of all GM NHS healthcare professionals on this. This consultation period is open until 5:00pm on Friday 31st March 2017. Comments should be submitted here after which it will be reviewed, amended as required and then taken to GMMMG for final approval. The Pharmaceutical Industry is invited to comment on factual inaccuracies only.

Interface Prescribing Subgroup

9.2.17

The minutes of October 2016 meeting of Interface Prescribing Subgroup have now been published and are available on site.

<< Back

Line

TERMS AND CONDITIONS    |    CONTACT US    |    ABOUT US    |    ARCHIVE

RSS Feed
 
spacer